MedTrace Logo

Low-dose Buprenorphine Initiation for Opioid Use Disorder

NCT05450718 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2025-09-17

No results posted yet for this study

Summary

The purpose of this study is to test whether low-dose buprenorphine initiation for treatment of opioid use disorder is safe and effective.

Conditions

Interventions

DRUG

buprenorphine-naloxone

Low-dose initiation of buprenorphine-naloxone protocol

DRUG

buprenorphine-naloxone

Standard clinical guidelines for a two-day buprenorphine-naloxone initiation

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • Montefiore Medical Center

    lead OTHER

Principal Investigators

  • Benjamin T Hayes, MD, MS, MPH · Montefiore Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-11
Primary Completion
2027-03-17
Completion
2027-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05450718 on ClinicalTrials.gov